跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
VYZULTA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
VYZULTA
Authorized
STANDARD
VYZULTA
bausch & lomb inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
d13f71da7a22ad8c
Company
bausch & lomb inc
Type
Standard
Approval Details
Approval Id
d13f71da7a22ad8c
Drug Approval Canada Name
VYZULTA
Product Name
VYZULTA
Status
Marketed
Status Date
2019-05-17
Original Market Date
2019-05-17
Din
02484218
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Ophthalmic
Schedule
Prescription
Ahfs
52:40.28
Atc Original
S01EE06 LATANOPROSTENE BUNOD
Atc Name
s 01 ee 06
Aig Number
0161070001
Company Name
bausch & lomb inc
Company Address
1400 N Goodman Street, Rochester, New York, United States, 14609
Active Ingredients
LATANOPROSTENE BUNOD
0.024 % / W/V
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
d13f71da7a22ad8c
Type
Standard
Back to Health Canada Approvals